Clinical trials: Fibroblast
Fibroblast Growth Factor-21, Fasting
Serum Fibroblast Growth Factor-21 Levels During Prolonged Fasting
The investigators hypothesized that serum FGF21 levels would increase with prolongation of the fasting period. The investigators also hypothesized that food intake and body composition would change.
- Trial name
- NCT05792982
- Testing
- 12 hour fasting for 29 days
- Where
- Turkey (Türkiye)
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Hacettepe University
Growth Disorders
Evaluate the Effect of Growth Hormone (GH) Treatment on Fibroblast Growth Factor 23, a Known Phosphaturic Agent
The purpose of this study is to evaluate the effect of growth hormone treatment on phosphorus levels in the body. Phosphorus is an important mineral for bone growth.
- Trial name
- NCT00334945
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Lax Skin, Improve Facial Wrinkles
In Vivo Study to Evaluate Tissue Remodeling Via Fibroblast Stimulation Following a Single SofWave Treatment
Open-label, non-randomized single-arm prospective, single-center, self-controlled clinical study.
- Trial name
- NCT07685821
- Testing
- Sofwave
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Sofwave Medical LTD
Neoplasm
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma
The primary purpose of this study is to evaluate objective response rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of erdafitinib in a molecularly-defined subset of Asian participants with…
- Trial name
- NCT02699606
- Testing
- Erdafitinib
- Where
- 6 sites in China, South Korea and 1 more
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Spinal Cord Injury at C5-Th10 Level With Complete Lesion, Spinal Cord Transection
Autologous Bulbar Olfactory Ensheathing Cells and Nerve Grafts for Treatment of Patients With Spinal Cord Transection
The purpose of this experimental therapy is to evaluate the safety and efficacy of transplantation of autologous olfactory ensheathing cells (OECs) and olfactory nerve fibroblasts (ONFs) obtained from the olfactory bulb with…
- Trial name
- NCT03933072
- Testing
- obtaining of autologous human olfactory bulb, autologous sural nerve preparation, production of Glial Neuropatch, microsurgical reconstruction of the transected spinal cord with autologous Glial Neuropatch-nerve bridges
- Where
- Poland
- Volunteers
- 2 people
- Sponsor
- Nicholls Spinal Injury Foundation
Myocardial Fibrosis, Heart Failure
⁶⁸Ga-FAPI PET/CT for Cardiac Fibrosis in Heart Failure
Heart failure (HF) is a clinical syndrome with increasing incidence and prevalence, associated with high morbidity, mortality, and economic impact, despite therapeutic advances.
- Trial name
- MY-FAPI (NCT07296081)
- Testing
- 68Ga-FAPI PET/CT
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- University of Coimbra
Schizophrenia
Schizophrenia, Related Troubles and Glutathione: Clinical Trial. Effects of Oral Administration of N-Acetylcysteine (NAC) on the Brain Glutathione Level and on the Symptoms of Schizophrenia
The results of the study "schizophrenia, related disorders and glutathione" conducted at the Laboratory of Psychiatric Neuroscience (LUNEP) DUPA of Lausanne, reinforce the hypothesis proposed that a deficit intracerebral…
- Trial name
- NCT01506765
- Testing
- N-Acetyl-Cysteine (NAC)
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Coronary Disease, Coronary Heart Disease
Fibroblast Growth Factor-1 (FGF-1) for the Treatment of Coronary Heart Disease
Treatment for no-option heart patients with coronary artery disease. Procedure includes the injection into the heart of a protein growth factor, administered by the Biological Delivery Systems MyoStar injection and mapping…
- Conditions
- Coronary Disease, Coronary Heart Disease, Myocardial Ischemia, Coronary Arteriosclerosis
- Trial name
- NCT00117936
- Testing
- Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141) - low dose, Human Recombinant Fibroblast Growth Factor-1 (FGF1-141) - high dose
- Volunteers
- 150 people
- Sponsor
- Venturis Therapeutics, Inc.
Neoplasms, Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma
The purpose of this study is to determine a dose for future development and to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy profiles of JNJ-42756493 in Japanese and other Asian patients with advanced or…
- Conditions
- Neoplasms, Lymphoma, Adenocarcinoma, Esophagogastric Junction
- Trial name
- NCT01962532
- Testing
- Part 1: JNJ-42756493, Part 2: JNJ-42756493
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
Urothelial Carcinoma
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic…
- Trial name
- FIDES-02 (NCT04045613)
- Testing
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 95 people
- Sponsor
- Basilea Pharmaceutica
Crohn's Disease, Intestinal Fibrosis
68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease
This study is a prospective, case-control study evaluating whether the PET radiotracer 68Ga-FAPI-46 can detect fibrostenosing Crohn's disease in the small bowel.
- Conditions
- Crohn's Disease, Intestinal Fibrosis, Inflamatory Bowel Disease, Intestinal Strictures Related to Crohn´s Disease
- Trial name
- FAPI-PETCD (NCT07273188)
- Testing
- Ga68-FAPI-46
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Mayo Clinic
Skin Aging
Autologous Fibroblast Grafts in Facial Skin Regeneration
The purpose of this study is to evaluate the presence of skin changes after grafting of autologous fibroblasts by means of biophysical, histological, immunohistological, gene expression, glycosaminoglycan, and sensitivity…
- Trial name
- NCT01490554
- Testing
- autologous fibroblasts grafts
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Federal University of São Paulo
Bladder Cancer, NMIBC
A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors
This phase II trial studies how well Pemigatinib (an orally administered inhibitor of fibroblast growth factor receptors 1, 2, and 3) works in non-muscle invasive bladder cancer (NMIBC) patients with recurrent tumors and a prior…
- Conditions
- Bladder Cancer, NMIBC, Non-Muscle Invasive Bladder Cancer, Urothelial Carcinoma Recurrent
- Trial name
- NCT03914794
- Testing
- Pemigatinib
- Where
- 6 sites in United States
- Volunteers
- 30 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Neoplasms
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
This phase IB trial aims to identify anticancer activity of GSK3052230 in subjects with malignancies with abnormal dependence on FGF pathway signaling.
- Trial name
- NCT01868022
- Testing
- GSK3052230, paclitaxel, carboplatin
- Where
- 29 sites in United States, Belgium and 5 more
- Volunteers
- 65 people
- Sponsor
- GlaxoSmithKline
Urinary Bladder Neoplasms, Neoplasm Metastasis
Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Conditions
- Urinary Bladder Neoplasms, Neoplasm Metastasis, Carcinoma, Transitional Cell
- Trial name
- NCT07675057
- Testing
- Vepugratinib
- Sponsor
- Eli Lilly and Company
Malignant Tumors, Positron-Emission Tomography
FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application
This clinical trial aims to investigate the value of fibroblast activation protein PET/CT(PET/MR) in the diagnosis, staging, and evaluation of treatment outcomes in malignant tumors.
- Trial name
- NCT06270394
- Testing
- 68Ga-Fibroblast activation protein inhibitor
- Where
- China
- Volunteers
- 22 people
- Sponsor
- The First Affiliated Hospital of Anhui Medical University
Osteomalacia
Cinacalcet for Fibroblast Growth Factor 23 (FGF23)-Mediated Hypophosphatemia (Hypophosphatemic Rickets)
Background: Hypophosphatemia is a condition where a person has low levels of phosphorus in the blood. Low blood phosphorus can cause muscle and bone weakness (such as rickets) and teeth problems.
- Trial name
- NCT01748812
- Testing
- Osteomalacia
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Nasolabial Folds, Glabellar Crease
Autologous Fibroblast Transplantation in Facial Deformities
Beautiful skin requires maintenance of proper care. Skin exercise, protections from direct sunlight or harsh wind, and maintaining a healthy diet are some of the ways of having a good and radiant skin.
- Conditions
- Nasolabial Folds, Glabellar Crease, Deep Wrinkles of the Forehead, Acne Scars
- Trial name
- NCT01115634
- Testing
- Fibroblast, fibroblast and gel
- Where
- Iran
- Volunteers
- 60 people
- Sponsor
- Royan Institute
Rare Diseases, X-linked Hypophosphatemia
Burosumab in Children and Adolescents With X-linked Hypophosphatemia
In this prospective longitudinal cohort study we studied the efficacy and safety of burosumab in real-clinical practice for <13- and >13-years old children affected with X-linked hypophosphatemia.
- Trial name
- NCT04419363
- Testing
- Burosumab Injection
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Bicetre Hospital
Fibroblast
Fibroblast Growth Factor-23 (FGF-23) is Independently Associated With Left Ventricular Mass Index (LVMI) and Myocardial Performance Index (MPI) in Haemodialysis Patients
Serum FGF-23 levels will be measured in patients with a history of coronary artery disease and aortic valve calcifications.It will be searched whether patients with MPI>0.47 had higher or lower serum FGF-23 levels than those with…
- Trial name
- NCT01154842
- Where
- Turkey (Türkiye)
- Volunteers
- 128 people
- Sponsor
- Diskapi Teaching and Research Hospital